Aclidinium inhibits proliferation and metastasis of ovarian cancer SKOV3 cells via downregulating PI3K/AKT/mTOR signaling pathway

Qiao,Juan; Wang,Wei-Jing; Zhang,Yuan

doi:10.3892/ol.2018.9460

Aclidinium inhibits proliferation and metastasis of ovarian cancer SKOV3 cells via downregulating PI3K/AKT/mTOR signaling pathway

Authors:
- Juan Qiao
- Wei-Jing Wang
- Yuan Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China, Gynecology Department Five of The Harbin Red Cross Center Hospital, Harbin, Heilongjiang 150076, P.R. China, Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570203, P.R. China
Published online on: September 19, 2018 https://doi.org/10.3892/ol.2018.9460
Pages: 6417-6422
Copyright: © Qiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aclidinium, a muscarinic antagonist, is generally used to treat the respiratory system diseases whereas it is not clear whether aclidinium has therapeutic effect in ovarian cancer (OC). The aim of this study was to investigate the impact of aclidinium on OC and its potential mechanism. CCK-8 was employed to test the potential effect of aclidinium on SKOV3 cell proliferation. Transwell migration and invasion assay was performed to assess the influence of aclidinium on SKOV3 cell metastasis and invasion. Furthermore, flow cytometry apoptotic analysis was used to evaluate the effect of aclidinium on cell apoptosis. Finally, western blotting was applied to determine the changes of key proteins in apoptosis and PI3K/AKT/mTOR signaling pathway induced by aclidinium. The study showed that aclidinium had antiproliferative activity on SKOV3 cells. Simultaneously, aclidinium could significantly inhibit the number of migrated and invaded SKOV3 cells and markedly increased the SKOV3 cell apoptosis rate. Mechanistically, the expression of PI3K/AKT/mTOR signaling pathway related proteins were significantly inhibited in aclidinium treated SKOV3 cells. Our findings proposed a clue for further OC studies in preclinical and clinical treatment and aclidinium may be useful for the treatment of OC in the future.

View Figures

View References

1	Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G, Segal BH, et al: Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium: History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: Evidence from the ovarian cancer association consortium. Cancer Causes Control. 28:469–486. 2017. View Article : Google Scholar : PubMed/NCBI
2	Schorge JO, Clark RM, Lee SI and Penson RT: Primary debulking surgery for advanced ovarian cancer: Are you a believer or a dissenter? Gynecol Oncol. 135:595–605. 2014. View Article : Google Scholar : PubMed/NCBI
3	Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, Tang W, Jiang R, Cheng X, Wei Q, et al: BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer. 140:2051–2059. 2017. View Article : Google Scholar : PubMed/NCBI
4	Vogel TJ, Goodman MT, Li AJ and Jeon CY: Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecol Oncol. 146:340–345. 2017. View Article : Google Scholar : PubMed/NCBI
5	Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA; Gynecologic Oncology Group, : Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
6	Patel S, Kumar L and Singh N: Metformin and epithelial ovarian cancer therapeutics. Cell Oncol (Dordr). 38:365–375. 2015. View Article : Google Scholar : PubMed/NCBI
7	Spindel ER: Muscarinic receptor agonists and antagonists: Effects on cancer. Handb Exp Pharmacol. 208:451–468. 2012. View Article : Google Scholar
8	Hua N, Wei X, Liu X, Ma X, He X, Zhuo R, Zhao Z, Wang L, Yan H, Zhong B, et al: A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1. PLoS One. 7:e531702012. View Article : Google Scholar : PubMed/NCBI
9	Oppitz M, Möbus V, Brock S and Drews U: Muscarinic receptors in cell lines from ovarian carcinoma: Negative correlation with survival of patients. Gynecol Oncol. 85:159–164. 2002. View Article : Google Scholar : PubMed/NCBI
10	Shah N, Khurana S, Cheng K and Raufman JP: Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol. 296:C221–C232. 2009. View Article : Google Scholar : PubMed/NCBI
11	Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, Mark GP, Grando SA and Spindel ER: M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res. 67:3936–3944. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ni H, Soe Z and Moe S: Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 19:CD0105092014.
13	Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
14	Reid DJ and Carlson AA: Clinical use of aclidinium in patients with COPD. Int J Chron Obstruct Pulmon Dis. 9:369–379. 2014. View Article : Google Scholar : PubMed/NCBI
15	Fritz S, Wessler I, Breitling R, Rossmanith W, Ojeda SR, Dissen GA, Amsterdam A and Mayerhofer A: Expression of muscarinic receptor types in the primate ovary and evidence for nonneuronal acetylcholine synthesis. J Clin Endocrinol Metab. 86:349–354. 2001. View Article : Google Scholar : PubMed/NCBI
16	Mayerhofer A and Kunz L: A non-neuronal cholinergic system of the ovarian follicle. Ann Anat. 187:521–528. 2005. View Article : Google Scholar : PubMed/NCBI
17	Ami N, Koga K, Fushiki H, Ueno Y, Ogino Y and Ohta H: Selective M3 muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft model. J Pharmacol Sci. 116:81–88. 2011. View Article : Google Scholar : PubMed/NCBI
18	Pacini L, De Falco E, Di Bari M, Coccia A, Siciliano C, Ponti D, Pastore AL, Petrozza V, Carbone A, Tata AM, et al: M2 muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells. Cancer Biol Ther. 15:1489–1498. 2014. View Article : Google Scholar : PubMed/NCBI
19	Park YS and Cho NJ: Enhanced proliferation of SNU-407 human colon cancer cells by muscarinic acetylcholine receptors. BMB Rep. 41:803–807. 2008. View Article : Google Scholar : PubMed/NCBI
20	Russo P, Del Bufalo A, Milic M, Salinaro G, Fini M and Cesario A: Cholinergic receptors as target for cancer therapy in a systems medicine perspective. Curr Mol Med. 14:1126–1138. 2014. View Article : Google Scholar : PubMed/NCBI
21	Batra S, Popper LD and Iosif CS: Characterisation of muscarinic cholinergic receptors in human ovaries, ovarian tumours and tumour cell lines. Eur J Cancer. 29A:1–1306. 1993.
22	Dobbin ZC and Landen CN: The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
23	Mabuchi S, Kuroda H, Takahashi R and Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
24	Cazzola M: Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs. 10:482–490. 2009.PubMed/NCBI
25	Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 21:99–102. 1999. View Article : Google Scholar : PubMed/NCBI
26	Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 93:3636–3641. 1996. View Article : Google Scholar : PubMed/NCBI
27	Lau MT and Leung PC: The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
28	Xia B, Yang S, Liu T and Lou G: miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015. View Article : Google Scholar : PubMed/NCBI
29	Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR and Lu KH: Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer. 16:1668–1672. 2006. View Article : Google Scholar : PubMed/NCBI